ProQR Therapeutics to Present at Citizens Life Sciences Conference
ProQR Therapeutics N.V. (Nasdaq: PRQR), dedicated to transforming lives through innovative RNA therapies, has announced a presentation scheduled for the Citizens Life Sciences Conference in New York City. The event will take place on a specified date, and ProQR’s management team is set to delve into their groundbreaking work utilizing their proprietary Axiomer technology.
Live Webcast and Future Availability
A live webcast of ProQR’s fireside chat will be accessible through the company’s website. The information can be found in the “Investors & Media” section under the “Events” tab. Following the live session, a replay will be available for approximately 30 days, allowing interested stakeholders to catch up on the presentation and key discussions.
Introducing Axiomer Technology
Axiomer is a cutting-edge RNA base editing innovation that represents a new approach to medicinal development. It aims to generate medicines targeting various diseases by employing editing oligonucleotides (EONs). These EONs facilitate precise single nucleotide modifications in RNA. This revolutionary technology utilizes endogenous ADAR (Adenosine Deaminase Acting on RNA) enzymes within human cells to make these changes, thereby providing potential therapeutic benefits.
Mechanisms of Axiomer in Action
The Axiomer platform enables targeted edits—for instance, changing an Adenosine (A) to an Inosine (I”). Inosine is interpreted as Guanosine (G), which plays a critical role in reverting a disease-associated RNA mutation back to its normal state. This process can modulate protein expression, aiding in disease treatment and prevention by enhancing or altering the functionality of proteins involved.
About ProQR Therapeutics
ProQR Therapeutics is resolutely focused on developing transformative RNA therapies, driven by their commitment to addressing significant unmet medical needs. Their Axiomer platform uses the body’s own cellular machinery to execute precise edits in RNA, empowering the potential generation of new therapeutic options for both rare and prevalent diseases.
Commitment to Patient-Centric Solutions
Through its proprietary RNA repair technologies, ProQR is expanding its therapeutic pipeline while maintaining its deep commitment to patients and their families. By continually innovating and refining their approaches, ProQR aims to provide effective solutions that can change lives.
Investor Relations and Contact Information
For further inquiries, ProQR encourages communication through their investor relations team. Sarah Kiely serves as the primary contact for investors and the media. She can be reached via phone at +1 617 599 6228. For more detailed discussions about investment opportunities and collaborations, Peter Kelleher from LifeSci Advisors is also available at +1 617 430 7579.
Frequently Asked Questions
What is Axiomer technology?
Axiomer technology is ProQR's next-generation RNA base editing platform that allows precise, targeted modifications to RNA, potentially creating new therapeutic options.
When will ProQR present at the conference?
ProQR is scheduled to present at the Citizens Life Sciences Conference with the exact details available on their website.
How can I access the webcast?
The live webcast can be accessed from the “Investors & Media” section of ProQR’s website under the “Events” page and will be available for replay for a limited period.
Who can I contact for investor inquiries?
You can reach out to Sarah Kiely for media and investor inquiries at ProQR Therapeutics or contact Peter Kelleher for more detailed discussions.
What is the goal of ProQR's therapies?
ProQR aims to develop transformative RNA therapies that address significant medical needs, focusing on both rare and common diseases.
